MEway Pharma
Combined Solution for Nebulization and Inhalation
Company Overview
Snapshot
Founded in January 2014 by Eran Eilat, Joshua Altman, and Moshe Tshuva, MEway Pharma operated with 1–10 employees. The company raised $1M across one funding round from one investor. In September 2022, MEway Pharma ceased to operate.
Business overview
MEway Pharma specializes in developing solutions that integrate nebulization and inhalation technologies to enhance pulmonary drug delivery. The company's core product, the UltraFlow Nebulizer, is a handheld device designed for improved efficacy and shorter treatment times through fine particle emission, rapid flow rate, and a breath-actuated mechanism. MEway Pharma operates within the Health Tech & Life Sciences sector, focusing on medical devices, medical treatment, therapeutics, and drug delivery for global markets.
Log in to access full profile ›Company Intelligence Q&A
- What is MEway Pharma's primary focus?
- MEway Pharma focuses on developing combined nebulization and inhalation solutions to improve pulmonary drug delivery, aiming for enhanced efficacy and reduced treatment times.
- When was MEway Pharma founded?
- MEway Pharma was founded in January 2014.
- Who are the founders of MEway Pharma?
- The company was founded by Eran Eilat, Joshua Altman, and Moshe Tshuva.
- What is the status of MEway Pharma?
- MEway Pharma is currently non-active, having ceased operations in September 2022.
- What is the UltraFlow Nebulizer?
- The UltraFlow Nebulizer is MEway Pharma's handheld device that combines fine particle emission, rapid flow rate, and a breath-actuated mechanism to improve pulmonary drug delivery.